Form 4: Revance Therapeutics Director Ware Reports Share Disposal Following Merger Completion

Director Olivia C Ware reports the disposal of Revance Therapeutics shares and cancellation of restricted stock awards following the completion of a merger with Crown Laboratories.

Summary

• Olivia C Ware, a director of Revance Therapeutics, reported changes in beneficial ownership of the company's stock on February 6, 2025.
• The transactions are related to the merger between Revance Therapeutics and Crown Laboratories, Inc., which was finalized after a cash tender offer.
• Ware disposed of 16,675 shares of common stock at a price of $3.65 per share as part of the tender offer.
• Additionally, 15,000 restricted stock awards held by Ware were canceled and converted into the right to receive $3.65 per share due to the merger agreement.
• Following these transactions, Ware no longer directly owns any shares of Revance Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports the completion of a merger and the resulting transactions. There are no explicit positive or negative implications discussed.

Future Outlook

The document does not contain any specific forward-looking statements regarding the future outlook of the company, as the transactions relate to the completion of a merger.

Industry Context

This announcement reflects the completion of a merger transaction, which is a common occurrence in the biotechnology and pharmaceutical industries as companies seek to consolidate resources, expand product portfolios, or gain access to new technologies.

Stakeholder Impact

• Shareholders who tendered their shares received $3.65 per share in cash.
• Non-employee members of the Issuer board with restricted stock awards received $3.65 per share for their canceled awards.

Key Dates

Keywords

Revance Therapeutics, Crown Laboratories, Merger, Share Disposal, Director, Form 4, Beneficial Ownership, Stock Awards, Tender Offer